PURPOSE: To assess the trends of neoadjuvant chemotherapy (NAC) use since its introduction in our practice pathway in patients with cT2 + bladder cancer over a 20-year period. METHODS: This is a retrospective review of patients with cT2 + bladder cancer who underwent RC between 01/01/1998 and 01/01/2018 that aimed to evaluate the trends of NAC use and associated after implementation of a multidisciplinary treatment pathway. Cohorts were stratified into eras: pre-NAC (1998-2007) to NAC eras (2008-2018). Univariate analysis was conducted using Chi-squared test and Kaplan-Meier estimates were used to evaluate survival. RESULTS: In 904 total patients who underwent RC, there were 493 with cT2 + UCC disease. The rate of NAC peaked at 84.2% in the most recent year of analysis in all patients and was 100% in cT2 + patients eligible for NAC. There was an increased rate of complete response (downstage to pT0) from 8.7% to 15.8% (p = 0.018) between the two eras. Unadjusted survival analysis revealed improved overall survival (OS) between eras with 5-year OS 53.2% vs. 42.7% and 10-year OS 42.7% vs. 26.4% in the NAC vs. pre-NAC cohorts, respectively (p = 0.016). CONCLUSIONS: In this review of 20 years of experience, we report a dramatic rise in the use of NAC after adoption of a multidisciplinary pathway that is associated with expected survival benefits.
PURPOSE: To assess the trends of neoadjuvant chemotherapy (NAC) use since its introduction in our practice pathway in patients with cT2 + bladder cancer over a 20-year period. METHODS: This is a retrospective review of patients with cT2 + bladder cancer who underwent RC between 01/01/1998 and 01/01/2018 that aimed to evaluate the trends of NAC use and associated after implementation of a multidisciplinary treatment pathway. Cohorts were stratified into eras: pre-NAC (1998-2007) to NAC eras (2008-2018). Univariate analysis was conducted using Chi-squared test and Kaplan-Meier estimates were used to evaluate survival. RESULTS: In 904 total patients who underwent RC, there were 493 with cT2 + UCC disease. The rate of NAC peaked at 84.2% in the most recent year of analysis in all patients and was 100% in cT2 + patients eligible for NAC. There was an increased rate of complete response (downstage to pT0) from 8.7% to 15.8% (p = 0.018) between the two eras. Unadjusted survival analysis revealed improved overall survival (OS) between eras with 5-year OS 53.2% vs. 42.7% and 10-year OS 42.7% vs. 26.4% in the NAC vs. pre-NAC cohorts, respectively (p = 0.016). CONCLUSIONS: In this review of 20 years of experience, we report a dramatic rise in the use of NAC after adoption of a multidisciplinary pathway that is associated with expected survival benefits.
Authors: Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora Sternberg; Dean F Bajorin; Joaquim Bellmunt Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: Adrian S Fairey; Siamak Daneshmand; David Quinn; Tanya Dorff; Ryan Dorin; Gary Lieskovsky; Anne Schuckman; Jie Cai; Gus Miranda; Eila C Skinner Journal: Urol Oncol Date: 2012-11-07 Impact factor: 3.498
Authors: Charles C Peyton; Dominic Tang; Richard R Reich; Mounsif Azizi; Juan Chipollini; Julio M Pow-Sang; Brandon Manley; Philippe E Spiess; Michael A Poch; Wade J Sexton; Mayer Fishman; Jingsong Zhang; Scott M Gilbert Journal: JAMA Oncol Date: 2018-11-01 Impact factor: 31.777
Authors: Harras B Zaid; Sanjay G Patel; C J Stimson; Matthew J Resnick; Michael S Cookson; Daniel A Barocas; Sam S Chang Journal: Urology Date: 2013-11-11 Impact factor: 2.649
Authors: Andrea B Apolo; Herbert Barton Grossman; Dean Bajorin; Gary Steinberg; Ashish M Kamat Journal: Urol Oncol Date: 2012 Nov-Dec Impact factor: 3.498
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Miguel Gil; João Guerra; Vanessa Andrade; Mariana Medeiros; Thiago Guimarães; Rui Bernardino; Gil Falcão; Fernando Calais da Silva; Luís Campos Pinheiro Journal: Int Urol Nephrol Date: 2020-08-20 Impact factor: 2.370